Skip to main content
ANAPTYSBIO, INC logo

ANAPTYSBIO, INC — Investor Relations & Filings

Ticker · ANAB ISIN · US0327241065 LEI · 529900HH4WQT03IG1A12 US Professional, scientific and technical activities
Open in API
Filings indexed 636 across all filing types
Latest filing 2018-12-05 Director's Dealing
Country US United States of America
Listing US ANAB

About ANAPTYSBIO, INC

https://www.anaptysbio.com/

AnaptysBio, Inc. is a clinical-stage biotechnology company that focuses on the discovery and development of innovative immunology therapeutics. The company specializes in advancing immune cell-modulating antibodies designed to treat autoimmune and inflammatory diseases. Its therapeutic candidates target key pathways in the immune system to address significant unmet medical needs for various patient populations.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-12-05 English
10-Q
Interim / Quarterly Report Q3 2018
2018-11-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 8, 2018, by AnaptysBio, Inc. It announces the issuance of a press release regarding financial results for the nine months ended September 30, 2018. The document itself does not contain detailed financial statements or substantive financial data but rather references an attached press release (Exhibit 99.01). The length of the document is 3835 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces initial financial results for a period shorter than a full fiscal year (nine months).
2018-11-08 English
Regulatory Filings 2018
Regulatory Filings Classification · 95% confidence The document text appears to be heavily encoded or corrupted, containing no readable or meaningful financial, regulatory, or corporate information. There are no identifiable keywords, regulatory references, fiscal period dates, or document titles that would allow classification into any specific filing category. The length is 15,000 characters, but the content is not interpretable as a report or announcement. Given the lack of any discernible content, the document best fits the fallback category for miscellaneous or unclassifiable filings, which is Regulatory Filings (RNS).
2018-10-15 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated September 26, 2018, reporting the entry into a material definitive agreement related to an underwriting agreement for a stock offering. It details the issuance and sale of common stock, the underwriting agreement terms, and the intended use of proceeds. The document includes exhibits such as the underwriting agreement and legal opinions. There are no financial statements or comprehensive financial data presented, nor is this a full annual or quarterly report. The content focuses on a capital raising event and related agreements, which aligns with updates on company financing activities. Therefore, the document fits the category of Capital/Financing Update (CAP). The document length (7178 characters) and detailed description of the offering support this classification with high confidence.
2018-09-26 English
424B5
Capital/Financing Update Classification · 100% confidence The document is a prospectus supplement and accompanying prospectus related to a public offering of common stock by AnaptysBio, Inc. It includes detailed information about the offering, underwriting, risk factors, company overview, and use of proceeds. The document is filed pursuant to Rule 424(b)(5), which is a prospectus supplement filing under the Securities Act of 1933. This type of document is related to capital raising activities and provides detailed information about the securities being offered to investors. It is not a financial report, earnings release, management discussion, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms and underwriting information, confirming it is a financing update rather than a mere announcement or regulatory filing.
2018-09-26 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.